Australia's most trusted
source of pharma news
Saturday, 19 April 2025
Posted 16 April 2025 AM
Australian researchers have described a new side-effect for a promising cancer drug on the agenda for the July PBAC meeting.
Haematologists from Peter Mac, Royal Melbourne Hospital, and the University of Melbourne reported three cases of enterocolitis after treatment with Roche's bispecific antibody Columvi for B-cell non-Hodgkin lymphoma.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.